Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.04, Bloomberg Earnings reports. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. The company had revenue of $6.18 million for the quarter, compared to analyst estimates of $5.35 million.

Cytokinetics, (CYTK) traded up 9.37% during trading on Friday, hitting $14.00. 403,749 shares of the stock were exchanged. Cytokinetics, has a 12 month low of $8.77 and a 12 month high of $17.20. The stock’s market cap is $751.32 million. The stock’s 50 day moving average price is $14.69 and its 200 day moving average price is $14.02.

A number of analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Cytokinetics, in a research report on Friday. Morgan Stanley restated an “overweight” rating and issued a $25.00 target price (up from $24.00) on shares of Cytokinetics, in a research note on Friday, October 6th. Seaport Global Securities restated a “buy” rating and issued a $24.00 target price on shares of Cytokinetics, in a research note on Friday, October 6th. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 target price on shares of Cytokinetics, in a research note on Tuesday, September 26th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Cytokinetics, in a research note on Sunday, September 17th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.64.

COPYRIGHT VIOLATION NOTICE: “Cytokinetics, Incorporated (CYTK) Issues Earnings Results, Beats Expectations By $0.04 EPS” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/27/cytokinetics-incorporated-cytk-issues-earnings-results-beats-expectations-by-0-04-eps.html.

In related news, insider Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $12.47, for a total value of $141,509.56. Following the completion of the transaction, the insider now owns 21,570 shares in the company, valued at $268,977.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Santo J. Costa sold 5,000 shares of Cytokinetics, stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $14.00, for a total transaction of $70,000.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $70,000. The disclosure for this sale can be found here. Insiders sold a total of 177,990 shares of company stock worth $2,628,996 over the last three months. Insiders own 7.20% of the company’s stock.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Earnings History for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.